1162 LETTERS TO THE EDITOR

Wuthrich B: Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy 23:145-153, 1993

Wehrmann W. Reinhold U. Kukel S. Franke N. Uerlich M. Krevsel HW: Selective alterations in natural killer cell subsets in patients with atopic dermatitis. Int Arch Allergy Appl Immunol 92:318-322, 1990

Lack of Association Between Promoter Polymorphism of the Tumor Necrosis Factor-a Gene and Psoriatic Arthritis in **Japanese** Patients

To the Editor:

The analysis of population-specific human leukocyte antigen (HLA) has provided evidence that susceptibility to psoriasis is linked to HLA with racial differences (Henseler, 1997). Tumor necrosis factor- α (TNF- α) gene is also mapped within the HLA region and its product has been reported as one of the most important cytokines in the pathogenesis of psoriasis (Uyemura et al, 1993). Recently, Höhler et al (1997) reported in this journal a significant increase of subjects carrying A at position -238 of TNF- α gene promoter region in the psoriatic arthritis (PsA) group, as well as in that of early-onset psoriasis vulgaris (PsV). These findings, however, are still controversial (Jacob et al, 1999; Höhler, 1999). Jacob et al (1999) have also shown in the journal that promoter polymorphism at -238 of the TNF- α gene was not associated with early onset PsV when tested by the transmission disequilibrium test. Very recently, it has been demonstrated that an increased frequency of the TNF-238.A (A at -238) allele detected only in male patients but not in female patients with early-onset PsV (Reich et al, 2000). On the other hand, there are only a few reports on whether polymorphism of the TNF- α promoter region and PsA are associated or not, because only a few cases are investigated. Moreover, three new polymorphisms at positions -1031 (T to C change), -863 (C to A), and -857 (C to T) have been identified in the Japanese population (Higuchi et al, 1998). In this study we evaluated the association between promoter polymorphism of the TNF- α gene and PsA in the Japanese population.

Twenty Japanese patients (eight females and 12 males) suffering from PsA were studied (the median age was 44 y, ranged from 25 to 70). The control population consisted of 87 locally recruited, unrelated volunteers (21 female and 67 males with a median age of 52 y ranged from 15 to 81). Peripheral blood mononuclear cells were separated by the Ficoll method for isolation of genomic DNA. A 1042 bp DNA fragment of the 5' flanking region of the TNF- α gene at position -1107 to -66 was amplified by PCR with a sense primer 5'-GCTTGTGTGTGTGTGTGTGTGTGTGG-3' and an anti-sense primer 5'-GGACACAAGCATCAAGG-3' (Higuchi *et al*, 1998). Polymerase chain reaction (PCR) products were run on ethidium bromide-stained agarose gel, and then excised DNA bands from the gel were purified using a GENECLEAN II kit (BIO 101, La Jolla, CA). These purified PCR products were directly sequenced by the dideoxy nucleotide dye terminator cycle sequencing method using two different primers, 5'-GCTTGTGTGTGTGTGTGTGTGTGTGTGTGG-3' (Higuchi et al, 1998) for the polymorphism at -1031, -863, and -857, and 5'- TTCCTGCATCCTGTCTGGAA-3' (D'Alfonso and Richiardi, 1994) for those at -308 and -238, respectively.

As shown in Table I, all patients with PsA studied have a genotype G/G at both -238 and -308, whereas 4.6% (four of 87) and 3.4% (three of 87) of controls have a genotype G/A at -238 and -308, respectively. Gene frequencies for the TNF-238A allele in the Japanese controls were similar to those reported by the authors for West European Caucasians (2.3% vs 3.5%) (Höhler et al, 1997) and the previous report for Japanese patients (2.3% vs 2.0%) (Higuchi et al, 1998). The frequencies for the TNF-308A (A at -308) allele in the Japanese controls, however, were less than those reported by the authors for West European Caucasians (2.9% vs 10%) (Höhlet et al, 1997), whereas no difference was seen between this study and the previous one (2.9% vs 1.7%) (Higuchi et al, 1998). Furthermore, we found no significant increase of subjects carrying C, A, and T at positions -1031, -863, and -857, respectively (Table I). In this region the frequency of alleles -1031C (C at -1031), -863A (A at -863), and -857T (T at -857) is similar to that previously reported by Higuchi et al (1998) (12.6% vs 16.0% for -1031C; 15.5% vs 14.0%, -863A; 15.5% vs 17.7%, -857T).

These results are quite different from those reported by Höhler et al (1997). In their report, 32% (20 in 62) of PsA patients have genotype G/A at -238, whereas 7% of controls (seven of 99) have the genotype (Höhler *et al*, 1997). We calculated on gene frequencies for the TNF-238A allele in PsA patients 16.1% from the data demonstrated. The discrepancy does not seem to depend on the racial difference, because gene frequencies for the TNF-238A allele in their controls were not different from the data by our or other studies (3.5% vs 2.3% or 2.0%) (Höhlet et al, 1997; Higuchi et al, 1998). Although a small number of PsA cases was investigated, this study clearly shows that promoter polymorphism at -238 of the TNF- α gene is not associated with PsA in the Japanese population as well as at other positions, including -1031, -863, -857, and -308.

This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas (C) "Medical Genome Science" from the Ministry of Education, Science, Sports and Culture of Japan (No. 12204079).

> Yoshiaki Hamamoto, Hiroaki Tateno, Toshiko Ishida, Masahiko Muto Department of Dermatology and Biomolecular Sensing, School of Medicine Yamaguchi University, Ube, Yamaguchi, Japan

REFERENCES

- D'Alfonso S, Richiardi PM: A polymorphic variation in a putative regulation box of the TNF-A promoter region. *Immunogenetics* 39:150–155, 1994 Henseler T: The genetics of psoriasis. *J Am Acad Dermatol* 37:S1–11, 1997 Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K:
- polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens 51:605–612, 1998

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY

Manuscript received August 10, 2000; accepted for publication September 26, 2000.

Reprint requests to: Dr. Masahiko Muto, Department of Dermatology, School of Medicine Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan. Email: mmuto@po.cc.yamaguchi-u.ac.jp

Position Genotype	PsA		Control	
	Number (%)	Allele (frequency, %)	Number (%)	Allele (frequency, %)
T/T	16 (80.0)		65 (74.7)	
	· · /	-1,301T (90.0)	· · /	-1,301T (87.4)
-1301 T/C C/C C/C	4 (20.0)		22 (25.3)	
		-1,301C (10.0)		-1,301C (12.6)
	0 (0.0)		0 (0.0)	
	15 (75.0)		63 (72.4)	
	· · · ·	-863C (85.0)		-863C (84.5)
–863 C/A A/A C/C	4 (20.0)		21 (24 1)	
	. (20.0)	-863A (15.0)	== (=)	-863A (155)
	1 (5.0)	00011 (1010)	3 (3 5)	00011 (1010)
	14 (70.0)		62 (71.3)	
		-857C (82.5)		-857C (84.5)
–857 C/T T/T G/G	5 (25.0)		23 (26.4)	× /
	· · /	-857T (17.5)	· · /	-857T (15.5)
	1 (5.0)		2 (2.3)	
	20 (100)		83 (95.4)	
		-308G (100.0)	· · · ·	-308G (97.1)
–308 G/A A/A G/G	0 (0)		3 (3.4)	
		-308A (0.0)	. ,	-308A (2.9)
	0 (0)		1 (5.0)	
	20 (100)		83 (95.4)	
		-238G (100.0)		-238G (97.7)
–238 G/A A/A	0 (0)		4 (4.6)	
		-238A (0.0)		-238A (2.3)
	0 (0)		0 (0.0)	
	Genotype T/T T/C C/C C/C C/A A/A C/C C/T T/T G/G G/A A/A G/G G/A A/A	$\begin{array}{c c} PsA \\ \hline \mbox{Number (\%)} \\ \hline \mbox{T/T} & 16 (80.0) \\ T/C & 4 (20.0) \\ C/C & 0 (0.0) \\ C/C & 0 (0.0) \\ C/C & 15 (75.0) \\ \hline \mbox{C/C} & 4 (20.0) \\ \hline \mbox{C/C} & 1 (5.0) \\ C/C & 1 (5.0) \\ C/C & 5 (25.0) \\ C/T & 5 (25.0) \\ C/T & 5 (25.0) \\ \hline \mbox{T/T} & 1 (5.0) \\ C/T & 5 (25.0) \\ \hline \mbox{T/T} & 1 (5.0) \\ C/T & 0 (0) \\ \hline \mbox{A/A} & 0 $	$\begin{array}{ c c c c } \hline PsA & & & & & \\ \hline \mbox{Genotype} & Number (\%) & Allele (frequency, \%) \\ \hline \mbox{T/T} & 16 (80.0) & & & & & \\ \mbox{T/C} & 4 (20.0) & & & & & & \\ \mbox{T/C} & 4 (20.0) & & & & & & \\ \mbox{C/C} & 15 (75.0) & & & & & & \\ \mbox{C/C} & 15 (75.0) & & & & & & \\ \mbox{C/C} & 15 (75.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & & & & & \\ \mbox{C/C} & 14 (70.0) & & & & & & & & & & & & & & & & & & &$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Table I. TNF-α gene promoter polymorphism in 20 Japanese PsA patients and 87 controls

- Höhler T, Kruger A, Schneider Pm, et al: A TNF-α promoter polymorphism Is associated with Juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 109:562–565, 1997
- Höhler T: Promoter polymorphism at -238 of the tumor necrosis factor- α gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test. J Invest Dermatol 112:515–516, 1999
- Jacob N, Franz R, Marcus S-E, *et al*: Promoter polymorphism at -238 of the tumor necrosis factor-α gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test. *J Invest Dermatol* 112:514–515, 1999

Reply

To the Editor:

In a small study with 20 patients suffering from psoriatic arthritis, Hammamoto *et al* have investigated TNF- α promoter polymorphisms and failed to confirm the previously published (Höhler *et al*, 1997; Arias *et al*, 1997) association of psoriatic arthritis and psoriasis with a G to A transition polymorphism (TNF238.A) in the TNF- α promoter region. This polymorphism has attracted particular interest as it seems to influence the transcription of the TNF- α gene and decreases the production of TNF- α in particular by T lymphocytes (Kaluza *et al*, 2000). We have forwarded the hypothesis that this polymorphism could be an additional major histocompatibility complex (MHC) encoded susceptibility factor for the development of psoriasis favoring persistence of cutaneous skin infections, e.g. by streptococci. The TNF238A polymorphism is part of the ancestral haplotype B57.1 (TNF238.A-B57-Cw6) that has been linked to psoriasis. This is the most common haplotype in Reich K, Westphal G, Schulz T, et al: Combined analysis of polymorphisms of the tumor necrosis factor-α and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 113:214–220, 2000

Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701–705, 1993

Western European Caucasians with the disease (Jenisch et al, 1999). In addition, a number of other haplotypes have been associated with the occurrence of psoriasis, e.g. B13-Cw6, B8-Cw7, and B37-Cw6 (Jenisch et al, 1999), the latter being the most common disease associated haplotype in Japan (Imanishi et al, 1992). The strong haplotype conservation within the MHC makes the investigation of TNF- α polymorphisms in conjunction with HLA-B and Cw-alleles mandatory. Unfortunately, Hamamoto et al do not provide any data concerning HLA-B- and -Cw-allele haplotypes and frequencies in their psoriatic arthritis group. Considering the high frequency of the B37-Cw6 haplotype in Japanese psoriasis patients (Imanishi et al, 1992) it is not surprising that the authors do not find an association with the TNF238.A promoter variant, which is almost exclusively found on the B57-Cw6 haplotype. Nevertheless, the findings of this small study are interesting as they underline ethnic heterogeneity in the genetics of psoriasis. These results should be confirmed in a larger set of Japanese patients with psoriasis vulgaris and psoriatic arthritis including HLA-B and Cw alleles in the analysis.

Very recent data by Nair *et al* (2000) indicate that the MHC encoded PSORS1 susceptibility locus, which has been confirmed in a number of different studies, is located 100 kB telomeric to HLA-C. This group has identified a 60 kB fragment of the ancestral haplotype 57.1 that is shared by all identifiable risk haplotypes.

Manuscript received September 15, 2000; accepted for publication September 26, 2000.

Reprint requests to: Dr. Thomas Höhler, Meditzinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.